Xudong Tao

Practice Areas

Mr. Tao has over 25 years of experience practicing law in the PRC, focusing on debt and equity financing by PRC companies in both domestic and overseas markets, including advising issuers, underwriters and investors in connection with IPO and listing on the capital markets of the PRC, Hong Kong and USA, and post-listing restructuring, mergers and acquisitions, take-private and re-listing transactions.

Mr. Tao’s most recent representative deals include: (a) acting as PRC counsel to Grifols S.A. in its strategic investment in SSE-listed SRAAS in 2018 and divest in 2024; (b) acting as the issuer or underwriter’s PRC counsel to the HKIPO and listing on HKEX by QuantumParm, Qyun Therapeutics (2024), JF Wealth, DPC Dash (2023), AIM Vaccine (2022) and Microport Medbot (2021); (c) acting as the issuer’s counsel to IPO in the PRC and listing on PRC STAR Market by Biokin Pharma (2023), Hinova Pharma, Transwarp (2022), BeiGene (2021), Zelgen Biopharma and HitGen (2020), etc.

Mr. Tao has been selected as “Leading Lawyer” in capital market and mergers and acquisitions areas by Asialaw and IFLR since 2012. He is also ranked as a “Recommended Lawyer” by Chambers in corporate and commercial area (Band I) and a “Stand-out Lawyers” by Thomson Reuters in 2021.

Career

Member of the All China Bar Association

Languages Spoken

Mandarin, English

Education